AI Errors May Be Impossible to Eliminate – What That Means for Its Use in the FDA

Artificial Intelligence (AI) is rapidly transforming regulated industries, including pharmaceuticals, medical devices, and biologics. From predictive analytics and batch record review to deviation trending and inspection readiness, AI offers unprecedented efficiency. However, one fundamental reality remains: AI systems are not error-free—and may never be.

Unlike traditional software, AI systems—especially machine learning and generative AI—operate probabilistically. This means outputs can vary, contain bias, hallucinate information, or produce inconsistent results. In highly regulated environments governed by agencies such as the U.S. Food and Drug Administration, even small inaccuracies can have major compliance and patient safety implications.

This session explores the regulatory, ethical, and operational implications of AI’s inherent error potential. Participants will gain clarity on validation expectations, risk management strategies, and how to responsibly integrate AI within FDA-regulated systems while maintaining GMP compliance and data integrity.
Rather than asking whether AI can be perfect, this course reframes the question: How do we build controls, oversight, and governance models that make AI safe, compliant, and inspection-ready?

By the end of this session, participants will be able to:

• Explain why AI errors may be statistically unavoidable.
• Differentiate between deterministic software errors and probabilistic AI outputs.
• Interpret FDA expectations for AI-enabled tools in GMP environments.
• Apply risk-based validation principles to AI systems.
• Design oversight mechanisms and human-in-the-loop safeguards.
• Identify documentation requirements for AI governance.
• Establish monitoring metrics for AI performance drift.
• Prepare defensible responses for regulatory inspections involving AI tools.

• Regulatory Perspective: Understand how FDA expectations apply to AI-enabled systems.
• Risk-Based Thinking: Learn how to assess AI risk using ICH-aligned frameworks.
• Validation Challenges: Explore limitations of traditional Computer System Validation (CSV) when applied to adaptive AI systems.
• Inspection Readiness: Prepare for regulatory questions about algorithm transparency, explainability, and oversight.
• Practical Governance Models: Implement structured human-in-the-loop controls to mitigate AI risk.

Attendees will leave with a practical framework for deploying AI responsibly in regulated environments without compromising compliance or patient safety.

• The Nature of AI Error: Hallucinations, Bias, and Model Drift
• Deterministic vs. Probabilistic Systems in GMP
• Regulatory Expectations from the U.S. Food and Drug Administration
• AI Validation vs. Traditional CSV
• Risk Management Principles aligned with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH Q9)
• Data Integrity Considerations (ALCOA+)
• Governance Models for AI in Regulated Industries
• Human Oversight and Accountability Frameworks
• AI in Deviation Management, CAPA, and Trending
• Inspection Readiness and Audit Defense Strategies.

As AI tools increasingly support documentation review, predictive maintenance, deviation investigations, and even regulatory submissions, organizations face a new compliance frontier. Unlike traditional automation systems, AI models evolve, retrain, and may produce non-repeatable outputs. This challenges long-standing regulatory paradigms built on consistency and reproducibility.

The FDA has signaled growing interest in AI governance, transparency, and lifecycle oversight. Organizations must shift from a “validate once” mindset to a continuous monitoring and control strategy. This topic builds awareness of AI’s structural limitations and provides a defensible framework for compliant integration into regulated operations.

AI adoption is accelerating—but regulatory expectations remain stringent. Understanding how AI errors intersect with GMP requirements, validation standards, and FDA scrutiny is essential before implementation.

Professionals working in FDA-regulated and GMP environments, including:

• Quality Assurance (QA) Professionals
• Quality Control (QC) Analysts
• Regulatory Affairs Specialists
• Computer System Validation (CSV) Professionals
• IT and Data Governance Leaders
• Manufacturing and Operations Managers
• Compliance Officers
• Risk Management Professionals
• Digital Transformation Leaders.